drugset / Trial / NCT02409524
An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single site, Phase IIA clinical trial to investigate the safety and efficacy of an individualized anti-cancer vaccine (CRCL-AlloVax) in advanced HCC patients.
Timeline
- Start
- 2016-07
- Primary completion
- 2017-06
- Completion
- 2019-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AlloStim | Cell therapy | — | Other |
| Subject | AlloVax | Vaccine | — | Other |
| Subject | CRCL | Protein / enzyme biologic | — | Other |